{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T14:22:44Z","timestamp":1778595764616,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"am","delay-in-days":243,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0310113"],"award-info":[{"award-number":["JP20fk0310113"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["HBVA181T\/N236T"],"award-info":[{"award-number":["HBVA181T\/N236T"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["HBVL180M\/S202G\/M204V"],"award-info":[{"award-number":["HBVL180M\/S202G\/M204V"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jiac.2020.12.014","type":"journal-article","created":{"date-parts":[[2020,12,29]],"date-time":"2020-12-29T22:18:28Z","timestamp":1609280308000},"page":"702-706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics of 4\u2032-cyano-2\u2032-deoxyguanosine, a novel nucleoside analog inhibitor of the resistant hepatitis B virus, in a rat model of chronic kidney disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Mai","family":"Hashimoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Imoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-2367","authenticated-orcid":false,"given":"Keishi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Otagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2020.12.014_bib1","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.jiac.2019.03.014","article-title":"Hepatitis B virus infection: prevention of mother-to-child transmission and exacerbation during pregnancy","volume":"25","author":"Sasagawa","year":"2019","journal-title":"J\u00a0Infect Chemother"},{"key":"10.1016\/j.jiac.2020.12.014_bib3","doi-asserted-by":"crossref","first-page":"104744","DOI":"10.1016\/j.antiviral.2020.104744","article-title":"7-Deaza-7-fluoro modification confers on 4\u2032-cyano-nucleosides potent activity against entecavir\/adefovir-resistant HBV variants and favorable safety","volume":"176","author":"Hayashi","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.jiac.2020.12.014_bib4","first-page":"1","article-title":"Synthesis and evaluation of the anti-hepatitis B virus activity of 4\u2032-Azido-thymidine analogs and 4\u2032-Azido-2\u2032-deoxy-5-methylcytidine analogs: structural insights for the development of a novel anti-HBV agent","author":"Onitsuka","year":"2019","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"10.1016\/j.jiac.2020.12.014_bib5","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02143-18","article-title":"CMCDG, a novel nucleoside analog with favorable safety features, exerts potent activity against wild-type and entecavir-resistant hepatitis B virus","volume":"63","author":"Higashi-Kuwata","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2020.12.014_bib6","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1080\/15257770.2015.1037456","article-title":"Design, synthesis, and evaluation of anti-HBV activity of hybrid molecules of entecavir and adefovir: exomethylene acycloguanine nucleosides and their monophosphate derivatives","volume":"34","author":"Imoto","year":"2015","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"10.1016\/j.jiac.2020.12.014_bib7","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1002\/hep.27962","article-title":"4\u2032-modified nucleoside analogs: potent inhibitors active against entecavir-resistant hepatitis B virus","volume":"62","author":"Takamatsu","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jiac.2020.12.014_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/jphp.12897","article-title":"Pharmacokinetics studies of 4\u2032-cyano-2\u2032-deoxyguanosine, a potent inhibitor of the hepatitis B virus, in rats","volume":"70","author":"Hashimoto","year":"2018","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.jiac.2020.12.014_bib9","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1248\/bpb.b20-00372","article-title":"Pharmacokinetic properties of orally administered 4\u2032-cyano-2\u2032-deoxyguanosine, a novel nucleoside analog inhibitor of the hepatitis B virus, in viral liver injury model rats","volume":"43","author":"Hashimoto","year":"2020","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jiac.2020.12.014_bib12","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1248\/bpb.32.2041","article-title":"Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats","volume":"32","author":"Kadowaki","year":"2009","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.jiac.2020.12.014_bib13","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/jphp.12446","article-title":"Antioxidant and renoprotective activity of 2-hydroxypropyl-\u03b2-cyclodextrin in nephrectomized rats","volume":"68","author":"Anraku","year":"2016","journal-title":"J\u00a0Pharm Pharmacol"},{"key":"10.1016\/j.jiac.2020.12.014_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1081\/NCN-120037508","article-title":"Design, efficient synthesis, and anti-HIV activity of 4\u2019-C-cyano- and 4\u2019-C-ethynyl-2\u2019-deoxy purine nucleosides","volume":"23","author":"Kohgo","year":"2004","journal-title":"Nucleos Nucleot Nucleic Acids"},{"key":"10.1016\/j.jiac.2020.12.014_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2133\/dmpk.14.286","article-title":"Moment analysis program available on Microsoft Excel","volume":"14","author":"Tabata","year":"1999","journal-title":"Drug Metabol Pharmacokinet"},{"key":"10.1016\/j.jiac.2020.12.014_bib16","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1128\/AAC.00986-16","article-title":"Multiple drug transporters are involved in renal secretion of entecavir","volume":"60","author":"Yang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jiac.2020.12.014_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lfs.2011.03.018","article-title":"Organic anion and cation transporters are possibly involved in renal excretion of entecavir in rats","volume":"89","author":"Yanxiao","year":"2011","journal-title":"Life Sci"},{"key":"10.1016\/j.jiac.2020.12.014_bib18","first-page":"649","article-title":"Drug dosing in chronic kidney disease","volume":"89","author":"Gabardi","year":"2005","journal-title":"Med Clin"},{"key":"10.1016\/j.jiac.2020.12.014_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ejps.2015.02.010","article-title":"Decreased liver distribution of entecavir is related to down-regulation of Oat2\/Oct1 and up-regulation of Mrp1\/2\/3\/5 in rat liver fibrosis","volume":"71","author":"Xu","year":"2015","journal-title":"Eur J Pharmaceut Sci"},{"key":"10.1016\/j.jiac.2020.12.014_bib20","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/ki.2013.399","article-title":"Effects of chronic kidney disease and uremia on hepatic drug metabolism and transport","volume":"85","author":"Yeung","year":"2014","journal-title":"Kidney Int"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20304499?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X20304499?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:55:45Z","timestamp":1778594145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X20304499"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1341321X20304499"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2020.12.014","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacokinetics of 4\u2032-cyano-2\u2032-deoxyguanosine, a novel nucleoside analog inhibitor of the resistant hepatitis B virus, in a rat model of chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2020.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}